Filtered By:
Vaccination: AIDS Vaccine
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 3482 results found since Jan 2013.
Effect of Narrative Reports about Vaccine Adverse Events and Bias-Awareness Disclaimers on Vaccine Decisions: A Simulation of an Online Patient Social Network
Conclusions. Patient networks can influence vaccination decisions by delivering risk-related information. Disclaimers may help to reduce the influence if desired.
Source: Medical Decision Making - January 8, 2013 Category: Health Management Authors: Betsch, C., Renkewitz, F., Haase, N. Tags: Patient Decision Aids and Risk Perception Source Type: research
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Animal models in HIV-1 protection and therapy
Purpose of review: The purpose of this review is to highlight major advances in the development and use of animal models for HIV-1 research during the last year.
Recent findings: Animal model research during the last year has focused on the development and refinement of models; use of these models to explore key questions about HIV entry, immune control, and persistence; and key discoveries with these models testing therapeutic and vaccine concepts. Some of the greatest breakthroughs have been in understanding early events surrounding transmission, the effectiveness of broadly neutralizing human monoclonal antibodies as pa...
Source: Current Opinion in HIV and AIDS - April 13, 2015 Category: Infectious Diseases Tags: ANTIBODIES FOR PREVENTION AND THERAPY: Edited by John R. Mascola and Richard A. Koup Source Type: research
Rapidly Progressive Dementia and Myoclonus with Elevated CSF IgG Index in Young Adult Immigrants: Treatable, but Not Always with Immunosuppression (I4-2A)
CONCLUSIONS: Young adults with RPD, myoclonus, and elevated CSF IgG index may have SSPE. Upbringing in areas in which measles eradication had not yet been achieved can be an important diagnostic clue. EEG and measles antibodies in serum and CSF are useful, readily available diagnostic studies. Reports of accelerated disease course associated with steroids, pregnancy, and HIV/AIDS in patients with SSPE support the hypothesis that empiric immunosuppression could have worsened the outcome in these two patients.Disclosure: Dr. Jay has nothing to disclose. Dr. Zimmermann has nothing to disclose. Dr. DaSilva has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jay, C., Zimmermann, L., DaSilva, K. Tags: Infectious, Paraneoplastic, and Autoimmune Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis Data Blitz Presentations Source Type: research
Abstract B69: Cervical and anal HPV serotype-specific prevalence among high-risk indigent women in substance abuse recovery
Conclusion: The HPV serotypes observed in this study provide baseline HPV prevalence rates for monitoring future HPV vaccination efforts in this and similar underserved populations. This is significant since one of the fastest growing segments of the criminal population are women offenders serving time on probation for low level offenses related to drug activity and prostitution. HPV vaccination programs in this target population may need to be broadened to include mid-adult women and other serotypes in addition to HPV 16/18.Citation Format: Martha J. Felini, Oluwatosin Igenoza, Saritha Bangara, Kelechi Ukpaka, Opeyemi Jeg...
Source: Cancer Epidemiology Biomarkers and Prevention - April 14, 2016 Category: Cancer & Oncology Authors: Felini, M. J., Igenoza, O., Bangara, S., Ukpaka, K., Jegede, O., Gupta, S., Voskuhl, G. W., Kremer, T., Anderson, R., Qualls-Hampton, R. Tags: Screening and Early Detection: Poster Presentations - Proffered Abstracts Source Type: research
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine were evaluated in HIV-positive Spanish MSM. The prevalence of High Squamous Intraepithelial Lesions (HSIL) and genotypes of hig...
Source: AIDS Research and Therapy - July 18, 2017 Category: Infectious Diseases Authors: Carmen Hidalgo-Tenorio, Jessica Ram írez-Taboada, Concepción Gil-Anguita, Javier Esquivias, Mohamed Omar-Mohamed-Balgahata, Antonio SamPedro, Miguel Lopez-Ruz and Juan Pasquau Source Type: research
Therapeutic vaccination for HIV: hopes and challenges
Purpose of review
This review summarizes the recent landscape of HIV therapeutic vaccine research, emphasizing the results of randomized controlled trials that included analytical treatment interruption (ATI) to assess efficacy.
Recent findings
Therapeutic vaccines for HIV are designed to re-educate the host immune response in HIV-infected individuals to better control viral replication in the absence of antiretroviral therapy. No therapeutic vaccine has yet to induce long-term HIV remission following ATI in a randomized controlled trial. This is likely because the vaccines have not elicited a broad enough immune resp...
Source: Current Opinion in HIV and AIDS - August 3, 2018 Category: Infectious Diseases Tags: PROGRESS IN ACHIEVING LONG-TERM HIV REMISSION: Edited by Jean-Daniel Lelièvre and Timothy J. Henrich Source Type: research
Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
Presence of isolated anti-HBc antibody is common in HIV-infected patients in endemic areas and could be caused by prior HBV infection with loss of anti-HBs antibody. The role of vaccination in these patients r...
Source: AIDS Research and Therapy - May 3, 2019 Category: Infectious Diseases Authors: Nattinee Laksananun, Jutarat Praparattanapan, Wilai Kotarathititum, Khuanchai Supparatpinyo and Romanee Chaiwarith Tags: Research Source Type: research
Coevolution of HIV-1 and broadly neutralizing antibodies
Purpose of review
Exploring the molecular details of the coevolution of HIV-1 Envelope with broadly neutralizing antibodies (bNAbs) in infected individuals over time provides insights for vaccine design. Since mid-2017, the number of individuals described in such publications has nearly tripled. New publications have extended such studies to new epitopes on Env and provided more detail on previously known sites.
Recent findings
Studies of two donors – one of them an infant, the other with three lineages targeting the same site – has deepened our understanding of V3-glycan-directed lineages. A V2-apex-directed line...
Source: Current Opinion in HIV and AIDS - June 3, 2019 Category: Infectious Diseases Tags: BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz Source Type: research
Mumps Cases Disproportionately Affecting Persons Living with HIV Infection and Men Who Have Sex with Men - Chicago, Illinois, 2018
This report describes the use of spatiotemporal analysis to identify clusters of people with mumps and target public health response efforts in Chicago.
Source: CDC Morbidity and Mortality Weekly Report - July 16, 2020 Category: American Health Tags: HIV/AIDS HIV/AIDS and STDs Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety Men's Health MMWR Morbidity & Mortality Weekly Report Mumps Vaccination Source Type: news
Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals
Multi-types COVID-19 vaccines have shown safety and efficacy against COVID-19 in adults. Although current guidelines encourage people living with HIV (PLWH) to take COVID-19 vaccines, whether their immune resp...
Source: AIDS Research and Therapy - July 5, 2022 Category: Infectious Diseases Authors: Shi Zou, Mengmeng Wu, Fangzhao Ming, Songjie Wu, Wei Guo, Gifty Marley, Zhongyuan Xing, Zhiyue Zhang, Minxia Zeng, Chao Sun, Jianfeng Zhang, Weiming Tang and Ke Liang Tags: Research Source Type: research
Coinhibitory receptors and CD8 T cell exhaustion in chronic infections
Purpose of review: To describe the recent data on the role of coinhibitory receptors, such as PD-1, Tim-3, CD160, as mediators of the ‘exhaustion’ of virus-specific CD8 T cells in chronic infections and particularly in HIV.
Recent findings: Exhaustion of chronic virus-specific CD8 T cells is a dynamic process characterized by altered differentiation, impaired function, and compromised proliferation/survival profile of these cells. This process is mediated by coinhibitory receptors expressed on the surface of virus-specific CD8 T cells and an orchestrated function of centrally connected pathways. Coexpression of several...
Source: Current Opinion in HIV and AIDS - September 1, 2014 Category: Infectious Diseases Tags: CELL EXHAUSTION IN HIV-1 INFECTION: Edited by Daniel E. Kaufmann and Nabila Seddiki Source Type: research
Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life
Purpose of review: A wealth of recent animal model data suggests that as exciting possibilities for the use of antibodies in passive immunotherapy strategies continue to develop, it will be important to broadly consider how antibodies achieve anti-HIV-1 effect in vivo.
Recent findings: Beyond neutralization breadth and potency, substantial evidence from natural infection, vaccination, and studies in animal models points to a critical role for antibody Fc receptor (FcR) engagement in reducing risk of infection, decreasing postinfection viremia, and delaying viral rebound. Supporting these findings in the setting of HIV, the...
Source: Current Opinion in HIV and AIDS - April 13, 2015 Category: Infectious Diseases Tags: ANTIBODIES FOR PREVENTION AND THERAPY: Edited by John R. Mascola and Richard A. Koup Source Type: research
HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities
Purpose of review: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA).
Recent findings: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scale-up, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi...
Source: Current Opinion in HIV and AIDS - December 2, 2016 Category: Infectious Diseases Tags: Special Considerations and Populations Source Type: research
B-cell abnormalities and impact on antibody response in HIV infection
Purpose of review: The purpose of the present review is to provide an update on the current development in the field of broadly neutralizing antibodies (bNabs) and their potential use in the prevention and therapeutic settings, and an evaluation of the B-cell abnormalities that may impair antibody responses in HIV infection.
Recent findings: Major advances have been achieved in the characterization of bNabs directed against different vulnerable regions of HIV Envelope (Env). Recent observations have clearly demonstrated the ability of bNabs to prevent HIV infection in the nonhuman primate model of HIV infection and to sup...
Source: Current Opinion in HIV and AIDS - April 20, 2017 Category: Infectious Diseases Tags: HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf Wagner Source Type: research
